

# Carla Osiowy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4995322/publications.pdf>

Version: 2024-02-01

91  
papers

2,221  
citations

257357

24  
h-index

243529

44  
g-index

100  
all docs

100  
docs citations

100  
times ranked

2281  
citing authors

#	ARTICLE	IF	CITATIONS
1	Current challenges of severe acute respiratory syndrome coronavirus 2 seroprevalence studies among blood donors: A scoping review. <i>Vox Sanguinis</i> , 2022, 117, 476-487.	0.7	5
2	Development and Evaluation of a Molecular Hepatitis A Virus Assay for Serum and Stool Specimens. <i>Viruses</i> , 2022, 14, 159.	1.5	6
3	Hepatitis B Virus Genotype G: The Odd Cousin of the Family. <i>Frontiers in Microbiology</i> , 2022, 13, 872766.	1.5	4
4	Molecular epidemiology and clinical characteristics of hepatitis D virus infection in Canada. <i>JHEP Reports</i> , 2022, 4, 100461.	2.6	8
5	Canadian blood suppliers: An expanding role in public health surveillance?. <i>Canada Communicable Disease Report</i> , 2022, 48, 124-130.	0.6	6
6	Spontaneous Flares of Chronic Hepatitis B Virus in Hepatitis Be Antigen Negative Carriers Who Subsequently Clear Hepatitis B Surface Antigen. <i>Digestive Diseases and Sciences</i> , 2021, 66, 257-262.	1.1	1
7	Distinct Hepatitis B and HIV co-infected populations in Canada. <i>Journal of Viral Hepatitis</i> , 2021, 28, 517-527.	1.0	6
8	Identification and characterization of a G-quadruplex structure in the pre-core promoter region of hepatitis B virus covalently closed circular DNA. <i>Journal of Biological Chemistry</i> , 2021, 296, 100589.	1.6	18
9	Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management. <i>Viruses</i> , 2021, 13, 951.	1.5	31
10	Practical guidance for clinical laboratories for SARS-CoV-2 serology testing. <i>Canada Communicable Disease Report</i> , 2021, 47, 171-183.	0.6	12
11	Guide pratique à l'intention des laboratoires cliniques pour les tests de sérologie du SRAS-CoV-2. <i>Revue Des Maladies Transmissibles Au Canada</i> , 2021, 47, 187-200.	0.0	0
12	Editorial: Origin and Evolution of Hepatitis Viruses. <i>Frontiers in Microbiology</i> , 2021, 12, 740255.	1.5	0
13	Stability of SARS-CoV-2 IgG in multiple laboratory conditions and blood sample types. <i>Journal of Clinical Virology</i> , 2021, 142, 104933.	1.6	8
14	Evaluation of commercial SARS-CoV-2 serological assays in Canadian public health laboratories. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 101, 115412.	0.8	10
15	Hepatitis B vaccination for Canadian children: time for an adult conversation. <i>Cmaj</i> , 2021, 193, E26-E26.	0.9	0
16	Hepatitis B virus elimination status and strategies in circumpolar countries, 2020. <i>International Journal of Circumpolar Health</i> , 2021, 80, 1986975.	0.5	2
17	Rapid Diagnostics for Hepatitis B and C Viruses in Low- and Middle-Income Countries. <i>Frontiers in Virology</i> , 2021, 1, .	0.7	8
18	Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison. <i>PLoS ONE</i> , 2021, 16, e0261003.	1.1	24

#	ARTICLE	IF	CITATIONS
19	A189 NON-ALCOHOLIC FATTY LIVER DISEASE AND SEN-V INFECTION: AN INTERIM ANALYSIS. <i>Journal of the Canadian Association of Gastroenterology</i> , 2020, 3, 60-61.	0.1	0
20	Differences in HBV Replication, APOBEC3 Family Expression, and Inflammatory Cytokine Levels Between Wild-Type HBV and Pre-core (G1896A) or Basal Core Promoter (A1762T/G1764A) Mutants. <i>Frontiers in Microbiology</i> , 2020, 11, 1653.	1.5	13
21	Characterization of occult hepatitis B in high-risk populations in Kenya. <i>PLoS ONE</i> , 2020, 15, e0233727.	1.1	17
22	Does SEN-V and other non-A-E hepatotropic viruses contribute to the development and progression of non-alcoholic fatty liver disease?. <i>Medical Hypotheses</i> , 2020, 137, 109528.	0.8	0
23	Oncogenic HBV variants and integration are present in hepatic and lymphoid cells derived from chronic HBV patients. <i>Cancer Letters</i> , 2020, 480, 39-47.	3.2	18
24	Analysis of Hepatitis B Virus Genotype D in Greenland Suggests the Presence of a Novel Quasi-Subgenotype. <i>Frontiers in Microbiology</i> , 2020, 11, 602296.	1.5	5
25	Characterization of occult hepatitis B in high-risk populations in Kenya. , 2020, 15, e0233727.		0
26	Characterization of occult hepatitis B in high-risk populations in Kenya. , 2020, 15, e0233727.		0
27	Characterization of occult hepatitis B in high-risk populations in Kenya. , 2020, 15, e0233727.		0
28	Characterization of occult hepatitis B in high-risk populations in Kenya. , 2020, 15, e0233727.		0
29	Epidemiologic and clinical features of chronic hepatitis B virus infection in 8 Canadian provinces: a descriptive study by the Canadian HBV Network. <i>CMAJ Open</i> , 2019, 7, E610-E617.	1.1	22
30	Horizontal Transmission of Hepatitis B Virus From Mother to Child Due to Immune Escape Despite Immunoprophylaxis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2019, 68, e81-e84.	0.9	7
31	Hepatitis B virus (HBV) genome detection and genotyping in virally suppressed patients using nested polymerase chain reaction-based Sanger sequencing. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 93, 318-324.	0.8	10
32	Hepatitis B Virus Infection of Normal Hepatic Stem/Progenitor Cells. <i>Journal of Clinical and Experimental Hepatology</i> , 2019, 9, 34-42.	0.4	2
33	From infancy and beyondâ€¦ ensuring a lifetime of hepatitis B virus (HBV) vaccine-induced immunity. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2093-2097.	1.4	11
34	Deep sequencing shows lowâ€¦level oncogenic hepatitis B virus variants persists postâ€¦liver transplant despite potent antiâ€¦HBVâ€¦ prophylaxis. <i>Journal of Viral Hepatitis</i> , 2018, 25, 724-732.	1.0	13
35	Long-Term Follow-up and Quantitative Hepatitis B Surface Antigen Monitoring in North American Chronic HBV Carriers. <i>Annals of Hepatology</i> , 2018, 17, 232-241.	0.6	5
36	Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. <i>Canadian Liver Journal</i> , 2018, 1, 156-217.	0.3	56

#	ARTICLE	IF	CITATIONS
37	Occult hepatitis B virus persistence in liver transplant recipients despite prophylactic hepatitis B immune globulin and potent nucleos(t)ide analogues therapy. <i>Journal of Hepatology</i> , 2017, 66, S187-S188.	1.8	0
38	Transmission of hepatitis D virus between spouses: A longitudinal study of the first reported Canadian case. <i>IDCases</i> , 2017, 8, 37-41.	0.4	4
39	Compartmental HBV evolution and replication in liver and extrahepatic sites after nucleos(t)ide analogue therapy in chronic hepatitis B carriers. <i>Journal of Clinical Virology</i> , 2017, 94, 8-14.	1.6	22
40	Serological and molecular epidemiological outcomes after two decades of universal infant hepatitis B virus (HBV) vaccination in Nunavut, Canada. <i>Vaccine</i> , 2017, 35, 4515-4522.	1.7	9
41	Chronic hepatitis B carriers with acute on chronic liver failure show increased HBV surface gene mutations, including immune escape variants. <i>Virology Journal</i> , 2017, 14, 203.	1.4	6
42	Tracing hepatitis B virus (HBV) genotype B5 (formerly B6) evolutionary history in the circumpolar Arctic through phylogeographic modelling. <i>PeerJ</i> , 2017, 5, e3757.	0.9	29
43	Hepatitis B virus genotypes and unique recombinants circulating among outpatients in selected hospitals in Kenya. <i>International Journal of Infectious Diseases</i> , 2016, 45, 451-452.	1.5	1
44	Discordant diagnostic results due to a hepatitis B virus T123A HBsAg mutant. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 85, 328-333.	0.8	5
45	Dynamics of Serum Quantitative Hepatitis B Surface Antigen Testing in Assessing Nucleos(T)ide Analog Treatment Response and Disease Phenotype in Chronic Hepatitis B Patients in Canada. <i>Journal of Hepatology</i> , 2016, 64, S356.	1.8	1
46	Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog Therapy. <i>Current Treatment Options in Infectious Diseases</i> , 2016, 8, 177-193.	0.8	6
47	Hepatitis B infection is highly prevalent among patients presenting with jaundice in Kenya. <i>BMC Infectious Diseases</i> , 2016, 16, 101.	1.3	35
48	Characterization of Acute and Chronic Hepatitis B Virus Genotypes in Canada. <i>PLoS ONE</i> , 2015, 10, e0136074.	1.1	20
49	Detection of Hepatitis B Virus (HBV) Genomes and HBV Drug Resistant Variants by Deep Sequencing Analysis of HBV Genomes in Immune Cell Subsets of HBV Mono-Infected and/or Human Immunodeficiency Virus Type-1 (HIV-1) and HBV Co-Infected Individuals. <i>PLoS ONE</i> , 2015, 10, e0137568.	1.1	14
50	Public Health Response to a Large-scale Endoscopy Infection Control Lapse in a Nonhospital Clinic. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2015, 26, 77-84.	0.7	6
51	P0538 : Tracing HBV genetic history in the arctic: Evidence for a central asian HBV origin in Greenland. <i>Journal of Hepatology</i> , 2015, 62, S517.	1.8	0
52	HIV and hepatitis C virus co-infection in Kenya. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 1377-1378.	4.6	4
53	Hepatitis B virus (<scp>HBV</scp>) variants fluctuate in paired plasma and peripheral blood mononuclear cells among patient cohorts during different chronic hepatitis B (<scp>CHB</scp>) disease phases. <i>Journal of Viral Hepatitis</i> , 2015, 22, 416-426.	1.0	29
54	Hepatitis B Virus (HBV) Variants in Untreated and Tenofovir Treated Chronic Hepatitis B (CHB) Patients during Pregnancy and Post-Partum Follow-Up. <i>PLoS ONE</i> , 2015, 10, e0140070.	1.1	12

#	ARTICLE	IF	CITATIONS
55	Prevalence of chronic hepatitis B in Canada. <i>BMJ, The</i> , 2014, 349, g5398-g5398.	3.0	0
56	Establishing diagnostic criteria for occult hepatitis B virus infections in community based populations. <i>Journal of Medical Virology</i> , 2014, 86, 156-161.	2.5	5
57	Virological characteristics of occult hepatitis B virus in a North American cohort of human immunodeficiency virus type 1-positive patients on dual active anti-HBV/HIV therapy. <i>Journal of Clinical Virology</i> , 2014, 60, 347-353.	1.6	23
58	Genetic diversity of hepatitis B virus genotypes B6, D and F among circumpolar indigenous individuals. <i>Journal of Viral Hepatitis</i> , 2013, 20, 122-130.	1.0	37
59	Virology and clinical sequelae of long-term antiviral therapy in a North American cohort of hepatitis B virus (HBV)/human immunodeficiency virus type 1 (HIV-1) co-infected patients. <i>Journal of Clinical Virology</i> , 2013, 57, 103-108.	1.6	35
60	Characterization of hepatitis B virus genotypes and quantitative hepatitis B surface antigen titres in North American tertiary referral liver centres. <i>Liver International</i> , 2013, 33, 1363-1369.	1.9	20
61	A paucity of liver disease in Canadian Inuit with chronic hepatitis B virus, subgenotype B6 infection. <i>Journal of Viral Hepatitis</i> , 2013, 20, 890-896.	1.0	10
62	Distribution of Viral Hepatitis in Indigenous Populations of North America and the Circumpolar Arctic. <i>Antiviral Therapy</i> , 2013, 18, 467-473.	0.6	42
63	Pretreatment Resistance to Hepatitis C Virus Protease Inhibitors Boceprevir/Telaprevir in Hepatitis C Subgenotype 1A-Infected Patients from Manitoba. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2013, 27, 414-416.	1.8	8
64	The interaction between hepatitis B virus X protein and AIB1 oncogene is required for the activation of NF $\kappa$ B signal transduction. <i>Biochemical and Biophysical Research Communications</i> , 2012, 423, 6-12.	1.0	14
65	The prevalence and long term outcome of occult hepatitis B virus infections in community based populations. <i>Journal of Medical Virology</i> , 2012, 84, 1369-1375.	2.5	7
66	Hepatitis B Virus Genotype G forms core-like particles with unique structural properties. <i>Journal of Viral Hepatitis</i> , 2011, 18, 443-448.	1.0	12
67	Factors associated with vaccine failure and vertical transmission of hepatitis B among a cohort of Canadian mothers and infants. <i>Journal of Viral Hepatitis</i> , 2011, 18, 468-473.	1.0	99
68	Distinct geographical and demographic distribution of hepatitis B virus genotypes in the Canadian Arctic as revealed through an extensive molecular epidemiological survey. <i>Journal of Viral Hepatitis</i> , 2011, 18, e11-9.	1.0	36
69	Molecular characterization and phylogenetic analysis of full-genome HBV subgenotype D3 sequences from Serbia. <i>Infection, Genetics and Evolution</i> , 2011, 11, 1475-1480.	1.0	9
70	Molecular characterization of hepatitis B virus and a 9-year clinical profile in a patient infected with genotype I. <i>Journal of Medical Virology</i> , 2010, 82, 942-948.	2.5	26
71	607 THE UNIQUE STRUCTURAL PROPERTIES OF THE HEPATITIS B VIRUS GENOTYPE G CORE PROTEIN. <i>Journal of Hepatology</i> , 2010, 52, S239.	1.8	0
72	Genotype D amongst injection drug users with acute hepatitis B virus infection in British Columbia. <i>Journal of Viral Hepatitis</i> , 2009, 16, 64-73.	1.0	24

#	ARTICLE	IF	CITATIONS
73	684 IS VIRAL LOAD AT WEEK 48 PREDICTIVE OF ADEFOVIR RESISTANCE IN HBV PATIENTS RECEIVING ADEFOVIR FOR LAMIVUDINE RESISTANCE?. <i>Journal of Hepatology</i> , 2008, 48, S255.	1.8	1
74	Hepatitis B virus genotype G epidemiology and co-infection with genotype A in Canada. <i>Journal of General Virology</i> , 2008, 89, 3009-3015.	1.3	78
75	Classification of Hepatitis B Virus Genotype B into 2 Major Types Based on Characterization of a Novel Subgenotype in Arctic Indigenous Populations. <i>Journal of Infectious Diseases</i> , 2007, 196, 1487-1492.	1.9	92
76	Viral hepatitis in the Arctic. A review from a Circumpolar Workshop on Viral hepatitis, ICCH13. <i>Alaska Medicine</i> , 2007, 49, 193-203.	0.1	7
77	Detection of HBsAg mutants. <i>Journal of Medical Virology</i> , 2006, 78, S48-S51.	2.5	33
78	Detection of rtN236T and rtA181V/T Mutations Associated with Resistance to Adefovir Dipivoxil in Samples from Patients with Chronic Hepatitis B Virus Infection by the INNO-LiPA HBV DR Line Probe Assay (Version 2). <i>Journal of Clinical Microbiology</i> , 2006, 44, 1994-1997.	1.8	62
79	Molecular Evolution of Hepatitis B Virus over 25 Years. <i>Journal of Virology</i> , 2006, 80, 10307-10314.	1.5	130
80	Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. <i>Journal of Viral Hepatitis</i> , 2005, 12, 398-404.	1.0	45
81	Occult hepatitis B virus infection in a North American adult hemodialysis patient population. <i>Hepatology</i> , 2004, 40, 1072-1077.	3.6	130
82	Activation of AP-1 signal transduction pathway by SARS coronavirus nucleocapsid protein. <i>Biochemical and Biophysical Research Communications</i> , 2003, 311, 870-876.	1.0	115
83	Evaluation of the INNO-LiPA HBV Genotyping Assay for Determination of Hepatitis B Virus Genotype. <i>Journal of Clinical Microbiology</i> , 2003, 41, 5473-5477.	1.8	108
84	Sensitive Detection of HBsAg Mutants by a Gap Ligase Chain Reaction Assay. <i>Journal of Clinical Microbiology</i> , 2002, 40, 2566-2571.	1.8	33
85	Rapid detection of hepatitis B virus mutations using real-time PCR and melting curve analysis. <i>Hepatology</i> , 2002, 36, 723-728.	3.6	36
86	Detection of TT virus in human hair and skin. <i>Hepatology Research</i> , 2000, 16, 155-162.	1.8	19
87	Detection of Human Herpesvirus 6 DNA in Serum by a Microplate PCR-Hybridization Assay. <i>Journal of Clinical Microbiology</i> , 1998, 36, 68-72.	1.8	24
88	Direct Detection of Respiratory Syncytial Virus, Parainfluenza Virus, and Adenovirus in Clinical Respiratory Specimens by a Multiplex Reverse Transcription-PCR Assay. <i>Journal of Clinical Microbiology</i> , 1998, 36, 3149-3154.	1.8	129
89	Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes. <i>Journal of Virology</i> , 1997, 71, 4226-4232.	1.5	180
90	Neutralization of respiratory syncytial virus after cell attachment. <i>Journal of Virology</i> , 1995, 69, 1271-1274.	1.5	10

#	ARTICLE	IF	CITATIONS
91	Antibody-dependent enhancement of respiratory syncytial virus infection by sera from young infants. Vaccine Journal, 1994, 1, 670-677.	2.6	30